MDXH MDxHealth SA stock chart & analysis

Conviction 36HealthcareScan · Fri, Nov 13, 2026

Piercing line

MDxHealth SA (MDXH) closed at $0.1438 (+2.71%) on Nov 13, 2026. Its latest daily candle is a piercing line. Price is below its 50-day and below its 200-day moving average. RSI(14) 25, RS Rating 2, -96.7% from its 52-week high, -96.0% year to date. Sector: Healthcare · Diagnostics & Research.

MDXH$0.1438+2.71%

ResistanceSupportVol 14Insider buy

Loading chart…

Why MDXH moved

From the StockSetups movers recaps that covered MDXH, newest first. A recap states what was known that day.

Aug 14, 2026Close+76.3%
The catalyst was a pair of events disclosed after the previous close. MDxHealth reported Q2 2026 earnings on August 13, posting a net loss but beating revenue estimates and citing record sequential revenue growth.
Top Stock Movers Today — August 14, 2026: Why MDXH, CAPR, HTFL, IMXI & UMAC Surged →

MDxHealth SADiagnostics & Researchwww.mdxhealth.com ↗

Price0.1438

Change+2.71%

Gap-7.14%

Rel volume2.39×

Avg volume1.58M

Avg $ vol271.61K

SMA 200.1698

SMA 500.4344

SMA 2001.35

Price vs 50-66.89%

Price vs 200-89.31%

MA stackbearish

50/200 cross—

Supertrenddown · 0.2144

RSI (14)25

MACD hist0.01

MACD crossbull · 5d

Stoch %K / %D33 / 16

ADX (14)41

+DI / −DI13 / 39

RSI divergence—

MACD divergenceBullish

ATR %23.11%

ADR %13.20%

52w high4.35

52w low0.1141

From 52w high-96.69%

Above 52w low+26.03%

New 52w highNo

SqueezeOff

Bollinger width51.05%

%B0.20

Donchian pos28.05%

Donchian high0.2200

Donchian low0.1141

AVWAP (52w high)0.8419

vs AVWAP high-82.92%

AVWAP (52w low)0.1339

vs AVWAP low+7.39%

OBV trendFlat

Chaikin MF (20)0.02

Today vs 20d2.39×

Avg vol (14d)1.26M

Avg vol (20d)1.58M

Avg $ vol (20d)271.61K

Market cap7.39M

RS Rating2 / 99

RS 3m (vs SPY)-80.81%

RS 6m (vs SPY)-85.94%

RS line new highNo

Trend template0/8

Technical rank7.4

1 week-8.41%

1 month-76.18%

3 months-83.19%

6 months-83.90%

1 year-96.51%

YTD-95.97%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value7.39M

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryDiagnostics & Research

ExchangeNasdaq

Shares out—

Employees364

ListedThu, Feb 14, 2008

Free float42.51M

Float %44.6%

Short interest—

Days to cover—

Short volume47.8%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est−$0.16 vs −$0.07

Last surprise-128.6% miss

Setup gradeD

Conviction36 / 100

Pattern quality—

Tech rank7.4 / 100

Group rank14 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmPiercing line

MDXH technical analysis

Trend

MDXH is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 66.9% below the 50-day ($0.4344) and 89.3% below the 200-day ($1.35). ADX(14) at 41 points to a strong, established trend. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 25, in oversold territory. MACD crossed above its signal line 5 sessions ago. A bullish MACD divergence is in place. Its RS Rating of 2 puts its weighted 12-month performance ahead of about 2% of the US market.

Volume and volatility

Volume on the latest session ran 2.4× its 20-day average. It trades about $271,612 a day on average. ATR(14) is $0.0332, 23.1% of price — its typical daily range.

Key levels

The 52-week range is $0.1141 to $4.35; price is 96.7% below the high and 26.0% above the low. The VWAP anchored at the 52-week high is $0.8419, above price.

Performance

MDXH returned -8.4% (1 week), -76.2% (1 month), -83.2% (3 months), -83.9% (6 months), -96.5% (1 year), -96.0% (year to date).

About MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Diagnostics & Research · Listed 2008 · 364 employees

Insider activity

SEC Form 4 transactions in MDXH · open-market 1 buy

Insider	Side	Shares	Value	Traded	Filed
MVM Partners, LLC Director · Ordinary Shares · 2026-08-13	Buy	2.2M	$1000K	2026-08-13	2026-08-17
Bellano John Chief Commercial Officer · Share Option · 2026-06-01	Grant	116K	$0	2026-06-01	2026-06-03
HARDISON DON M Director · Share Option · 2026-06-01	Grant	10K	$0	2026-06-01	2026-06-03
Siegel Sanford Jay Director · Share Option · 2026-06-01	Grant	10K	$0	2026-06-01	2026-06-03
OConnell Brendan VP, Finance and Accounting · Share Option · 2026-06-01	Grant	65K	$0	2026-06-01	2026-06-03
OConnell Brendan VP, Finance and Accounting · Share Option · 2026-06-01	Grant	35K	$0	2026-06-01	2026-06-03
McGarrity Michael Chief Executive Officer · Share Option · 2026-06-01	Grant	612.4K	$0	2026-06-01	2026-06-03
Holder Michael Director · Share Option · 2026-06-01	Grant	10K	$0	2026-06-01	2026-06-03
Hoffman Koen Director · Share Option · 2026-06-01	Grant	10K	$0	2026-06-01	2026-06-03
Bellano John Chief Commercial Officer · Share Option · 2026-06-01	Grant	217K	$0	2026-06-01	2026-06-03

SEC filings

EDGAR filings in MDXH · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.